Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

摘要

Background Erenumab was effective and well tolerated in a pivotal clinical trial of episodic migraine that included subjects both naive to, and those who had failed, previous preventives. Here we evaluated the efficacy and safety of erenumab (70mg or 140mg) versus placebo in the subgroup of patients who had previously failed preventive treatment(s): 1 or 2 prior failed migraine preventive categories, and in patients who had never failed.